<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387488</url>
  </required_header>
  <id_info>
    <org_study_id>12-078</org_study_id>
    <secondary_id>CIV-16-01-014366</secondary_id>
    <nct_id>NCT03387488</nct_id>
  </id_info>
  <brief_title>Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans</brief_title>
  <acronym>VAPS</acronym>
  <official_title>Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans (VAPS - A Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Particularly in CRT (Cardiac Resynchronisation Therapy), limited accessibility of the&#xD;
      coronary sinus along with its branches and the mismatch between the region of latest left&#xD;
      ventricular (LV) contraction and an adequate epimyocardial vein frequently lead to therapy&#xD;
      failure and might even be responsible for the 30 % non-responders, although this aspect has&#xD;
      not been thoroughly investigated yet. Further complications such as postoperative micro-&#xD;
      (i.e. increased thresholds) or macro-dislodgement (i.e. loss of stimulation success) of the&#xD;
      LV electrodes are frequent complications leading to reoperation or a change of strategy. The&#xD;
      current transthoracic epimyocardial approach via mini-thoracotomy circumvents the aforesaid&#xD;
      obstacles and is regarded as the first-choice alternative approach. Participation in the&#xD;
      trial would prevent patients from this invasive, transthoracic approach and at the same time&#xD;
      allow the same degree of freedom in lead placement. Risks and complications are in this case&#xD;
      comparable to the open surgical approach but with a lower risk of intraoperative rib&#xD;
      fracture, postoperative pain with consecutive pulmonary hypo-ventilation and pneumonia.&#xD;
&#xD;
      Apart from the benefit of the single individual, societies benefit will include a much higher&#xD;
      responder rate in CRT patients and less lead-associated infections. Thoracotomy with breach&#xD;
      of the pleural cavity and single lung ventilation - a procedure that itself bears a high risk&#xD;
      for postoperative atelectasis, pleural effusion and infection will be avoided.&#xD;
&#xD;
      In patients on hemo-dialysis and patients who suffer from an infected pacemaker-system,&#xD;
      extravascular lead placement should be preferred. Again, the current open, transthoracic&#xD;
      epimyocardial approach via mini-thoracotomy is regarded as the first-choice alternative&#xD;
      approach.&#xD;
&#xD;
      Aim of this study is the validation of the feasibility of an alternative, minimal-invasive&#xD;
      therapy method for implanting a cardiac pacemaker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment:&#xD;
&#xD;
      Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker leads&#xD;
&#xD;
      Abridged Operation Protocol:&#xD;
&#xD;
      10 mm skin incision below the xiphoid process, blunt preparation towards the pericardial sac,&#xD;
      insertion of the endoscope-carrying trocar, opening of the pericardium with endoscopic&#xD;
      forceps, standardised inspection of the pericardial cavity, insertion of the bipolar&#xD;
      Stingray速 electrode via the endoscope working channel into pericardial space, implantation of&#xD;
      the electrode into designated epimyocardial site under endoscopic vision, pacing measurements&#xD;
      sensing, impedance, pacing threshold, interventricular delay (in CRT), panoramic fluoroscopy&#xD;
      for future controls, retraction of the endoscope/trocar, subcutaneous tunnelling and&#xD;
      connection of the respective electrode to:&#xD;
&#xD;
        -  existing, infraclavicular CRT device, suture in layers, wound dressing&#xD;
&#xD;
        -  a single- or dual-chamber pacemaker device implanted epigastrically, suture in layers,&#xD;
           wound dressing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative mortality</measure>
    <time_frame>30 days</time_frame>
    <description>The mortality will be documented as in the usual clinical routine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe operative complications</measure>
    <time_frame>7 days</time_frame>
    <description>Operative complications (e.g. cardiac tamponade, severe bleeding, infection, lead dislodgement, pacing thresholds etc.) will be documented.&#xD;
Reduction of procedure-related postoperative complications, particular pulmonic complications in comparison to thoracotomy:&#xD;
Duration of mechanical ventilation&#xD;
Occurrence of pulmonary ventilation disorders:&#xD;
Atelectasis&#xD;
Pleural effusion&#xD;
Pneumothorax&#xD;
Postoperative pain obtained by visual analog pain scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival will be documented as in the usual clinical routine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of ejection mechanism</measure>
    <time_frame>12 months</time_frame>
    <description>The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 1:&#xD;
Ejection fraction in percent, pre- and postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of ventricle coordination</measure>
    <time_frame>12 months</time_frame>
    <description>The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 2:&#xD;
Inter- and intraventricular delay in miliseconds, pre- and postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk reduction of endocarditis in dialysis/infected patients</measure>
    <time_frame>12 months</time_frame>
    <description>As compared to the literature</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dysrhythmia, Cardiac</condition>
  <condition>Heart Failure</condition>
  <condition>Pacemaker Electrode Infection</condition>
  <condition>Hemodialysis-Induced Symptom</condition>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>StingrayTM, Medtronic速</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>StingrayTM, Medtronic速</intervention_name>
    <description>Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic速</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Clinical Investigational Lead Model 09090</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This study will include patients who are planned to undergo a pacemaker therapy within&#xD;
        their regular medical care and who are eligible for an alternative approach for lead&#xD;
        placement (minimal-invasive pericardioscopic surgery):&#xD;
&#xD;
        I. Patients fulfilling current, sophisticated criteria for cardiac resynchronisation&#xD;
        therapy (CRT) (e.g. patients with symptomatic heart failure independent of functional&#xD;
        class, prolonged QRS-duration (especially left bundle branch block), severely depressed&#xD;
        systolic left ventricular function), but have a history of failed CRT lead implantation or&#xD;
        showed insufficient resynchronization after conventional CRT treatment, OR&#xD;
&#xD;
        II. Haemodialysis patients fulfilling the criteria for an implantation of a cardiac&#xD;
        pacemakers due to bradycardiac dysrhythmia, OR&#xD;
&#xD;
        III. Patients suffering from acute pacemaker-lead-infection, who require&#xD;
        system-explantation and concomitant implantation of a new system&#xD;
&#xD;
        Further inclusion criteria:&#xD;
&#xD;
          1. Patients aged 18 years or above&#xD;
&#xD;
          2. Adults who are contractually capable and mentally able to understand and follow the&#xD;
             instructions of the study personnel.&#xD;
&#xD;
          3. Signed informed consent prior to study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Euro Score II (http://www.euroscore.org/calc.html) &gt; 20 %&#xD;
&#xD;
          2. Patients in NYHA functional class IV&#xD;
&#xD;
          3. Previous cardiac surgery / sternotomy&#xD;
&#xD;
          4. Previous pericarditis&#xD;
&#xD;
          5. Gender-independent myocardial wall thickness less than 5 mm&#xD;
&#xD;
          6. Coexisting cardiac/vessel aneurysmata&#xD;
&#xD;
          7. Patients with myocardial infarction within the last 4 weeks&#xD;
&#xD;
          8. Pregnancy and breast-feeding&#xD;
&#xD;
          9. Patients who are accommodated at judicial or official requests&#xD;
&#xD;
         10. Patients with known anomalies of the cardiac anatomy&#xD;
&#xD;
         11. Patients for whom beclometasone dipropionate is contraindicated&#xD;
&#xD;
         12. Patients with bleeding disorders and coagulopathy&#xD;
&#xD;
         13. Patients with a life expectancy below 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nima Hatam, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital RWTH Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nima Hatam, Dr. med.</last_name>
    <phone>+492418089221</phone>
    <email>nhatam@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Nima Hatam, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

